Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

The G1 restriction point is critical for regulating the cell cycle and is controlled by the Rb pathway (CDK4/6-cyclin D1-Rb-p16/ink4a). This pathway is important because of its inactivation in a majority of human tumors. Transition through the restriction point requires phosphorylation of retinoblas...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelbert, Lawrence M., Cai, Shufen, Lin, Xi, Sanchez-Martinez, Concepcion, del Prado, Miriam, Lallena, Maria Jose, Torres, Raquel, Ajamie, Rose T., Wishart, Graham N., Flack, Robert Steven, Neubauer, Blake Lee, Young, Jamie, Chan, Edward M., Iversen, Philip, Cronier, Damien, Kreklau, Emiko, de Dios, Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169866/
https://www.ncbi.nlm.nih.gov/pubmed/24919854
http://dx.doi.org/10.1007/s10637-014-0120-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169866/
https://www.ncbi.nlm.nih.gov/pubmed/24919854
http://dx.doi.org/10.1007/s10637-014-0120-7

Ejemplares similares